DK2558575T3 - METHODS FOR GENERATION OF endogenous MARK PROTEIN. - Google Patents

METHODS FOR GENERATION OF endogenous MARK PROTEIN. Download PDF

Info

Publication number
DK2558575T3
DK2558575T3 DK11769489.3T DK11769489T DK2558575T3 DK 2558575 T3 DK2558575 T3 DK 2558575T3 DK 11769489 T DK11769489 T DK 11769489T DK 2558575 T3 DK2558575 T3 DK 2558575T3
Authority
DK
Denmark
Prior art keywords
sequence
cell
protein
tag
endogenous
Prior art date
Application number
DK11769489.3T
Other languages
Danish (da)
English (en)
Inventor
Dmitry Malkov
Nathan Zenser
Deborah Vassar
Fan Zhang
Hongyi Zhang
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Application granted granted Critical
Publication of DK2558575T3 publication Critical patent/DK2558575T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72—Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK11769489.3T 2010-04-13 2011-04-13 METHODS FOR GENERATION OF endogenous MARK PROTEIN. DK2558575T3 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US32371910P 2010-04-13 2010-04-13
US32370210P 2010-04-13 2010-04-13
US32369810P 2010-04-13 2010-04-13
US36701710P 2010-07-23 2010-07-23
US39066810P 2010-10-07 2010-10-07
US40885610P 2010-11-01 2010-11-01
US201161431957P 2011-01-12 2011-01-12
PCT/US2011/032218 WO2011130346A1 (en) 2010-04-13 2011-04-13 Methods for generating endogenously tagged protein

Publications (1)

Publication Number Publication Date
DK2558575T3 true DK2558575T3 (en) 2016-03-21

Family

ID=44799004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11769489.3T DK2558575T3 (en) 2010-04-13 2011-04-13 METHODS FOR GENERATION OF endogenous MARK PROTEIN.

Country Status (10)

Country Link
US (5) US20130065310A1 (OSRAM)
EP (2) EP2558574B1 (OSRAM)
JP (2) JP5841996B2 (OSRAM)
KR (2) KR20130054955A (OSRAM)
CN (3) CN102971421A (OSRAM)
BR (1) BR112012026379A2 (OSRAM)
CA (2) CA2795643C (OSRAM)
DK (1) DK2558575T3 (OSRAM)
ES (1) ES2565216T3 (OSRAM)
WO (3) WO2011130343A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180121665A (ko) 2010-07-23 2018-11-07 시그마-알드리치 컴퍼니., 엘엘씨 표적화 엔도뉴클레아제 및 단일-가닥 핵산을 사용하는 게놈 편집
US9012617B2 (en) * 2011-04-11 2015-04-21 The Trustees Of The University Of Pennsylvania Detection reagents for tyrosine kinase activity and methods of use thereof
MX354995B (es) * 2011-12-05 2018-03-27 Factor Bioscience Inc Metodos y productos para transfeccion de celulas.
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US10274499B2 (en) 2012-03-27 2019-04-30 The University Of Western Ontario SH2 domain variants
WO2013158309A2 (en) * 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Non-disruptive gene targeting
SG11201503059XA (en) * 2012-10-23 2015-06-29 Toolgen Inc Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
US20140315985A1 (en) 2013-03-14 2014-10-23 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
MX392639B (es) 2014-03-21 2025-03-24 Univ Leland Stanford Junior Vectores virales recombinantes para la integración de transgenes
DK3708579T3 (da) * 2014-04-01 2024-07-22 Biontech Cell & Gene Therapies Gmbh Claudin-6-specifikke immunreceptorer og t-celleepitoper
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
RU2746486C2 (ru) 2015-03-13 2021-04-14 Юниверсити Оф Мэрилэнд, Балтимор Универсальный антителоопосредованный биосенсор
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
ES2953925T3 (es) * 2015-11-04 2023-11-17 Fate Therapeutics Inc Ingeniería genómica de células pluripotentes
US20190192698A1 (en) * 2015-12-23 2019-06-27 Teknologian Tutkimuskeskus Vtt Oy A method for obtaining indicator signals from a cell
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP4047092B1 (en) 2016-04-13 2025-07-30 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN106800602B (zh) * 2017-01-22 2020-05-01 中国科学院生物物理研究所 一种可视化标记基因组位点的方法
US20190365818A1 (en) * 2017-02-09 2019-12-05 Allen Institute Genetically-tagged stem cell lines and methods of use
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019118879A1 (en) * 2017-12-14 2019-06-20 Donald Danforth Plant Science Center Homologous recombination via transcriptional activation
JP2021521877A (ja) * 2018-05-04 2021-08-30 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ． ＬＬＣ 宿主細胞タンパク質のレベルが低減した組換えタンパク質の生産
CN117904208A (zh) * 2018-12-30 2024-04-19 豪夫迈·罗氏有限公司 基于可检测标签与靶蛋白的CRISPR/Cas控制的整合而选择细胞的方法
WO2021055372A1 (en) * 2019-09-16 2021-03-25 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
CN113684228B (zh) * 2021-10-26 2022-03-11 天九再生医学(天津)科技有限公司 利用内参快速准确表征蛋白质相对丰度的方法
CN114703174B (zh) * 2022-04-12 2023-10-24 中国科学院海洋研究所 快速获得基因型和表型突变的CRISPR/Cas9基因敲除方法及应用
CN115948401A (zh) * 2022-12-19 2023-04-11 中国科学技术大学 一种多靶点rna靶向敲低系统及应用
CN120177781B (zh) * 2025-05-22 2025-08-12 南京师范大学 生物传感器及其应用和高通量筛选花姜酮生产菌的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192772B1 (en) * 1988-08-31 2007-03-20 The University Of Florida Research Foundations, Inc. Recombinant cells that highly express chromosomally-integrated heterologous gene
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US6495664B1 (en) * 1998-07-24 2002-12-17 Aurora Biosciences Corporation Fluorescent protein sensors of post-translational modifications
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
WO2003027253A2 (en) * 2001-09-26 2003-04-03 University Of North Carolina At Chapel Hill Variants of alpha-fetoprotein coding and expression sequences
EP3222715A1 (en) * 2003-08-08 2017-09-27 Sangamo BioSciences, Inc. Methods and compositions for targeted cleavage and recombination
US7402436B2 (en) * 2004-05-03 2008-07-22 City Of Hope Lentiviral vectors for site-specific gene insertion
WO2006017751A2 (en) * 2004-08-02 2006-02-16 Cellumen, Inc. Methods for the detection of molecular interactions within cells
US20060063231A1 (en) * 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20060171929A1 (en) * 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
WO2006094116A2 (en) * 2005-03-02 2006-09-08 The Albert Einstein College Of Medicine Of Yeshiva University Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20070155014A1 (en) * 2005-07-20 2007-07-05 Invitrogen Corporation Methods for increasing efficiency of homologous recombination
US20080305519A1 (en) * 2006-02-23 2008-12-11 Qing Lin Biochemical method for specific protein labeling
US20100009352A1 (en) * 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
US8936936B2 (en) * 2007-10-25 2015-01-20 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
EP2281050B1 (en) * 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
CA2734235C (en) * 2008-08-22 2019-03-26 Sangamo Biosciences, Inc. Methods and compositions for targeted single-stranded cleavage and targeted integration

Also Published As

Publication number Publication date
CN102959078A (zh) 2013-03-06
EP2558574B1 (en) 2015-03-18
CA2795636C (en) 2018-07-31
US20180134759A1 (en) 2018-05-17
BR112012026379A2 (pt) 2015-09-22
JP2013523181A (ja) 2013-06-17
EP2558575A4 (en) 2013-10-30
EP2558575B1 (en) 2015-12-16
US20180105564A1 (en) 2018-04-19
US20130059362A1 (en) 2013-03-07
CN102971421A (zh) 2013-03-13
KR20130055588A (ko) 2013-05-28
EP2558574A1 (en) 2013-02-20
WO2011130346A1 (en) 2011-10-20
US20130059388A1 (en) 2013-03-07
WO2011130345A1 (en) 2011-10-20
KR20130054955A (ko) 2013-05-27
CA2795643A1 (en) 2011-10-20
CN107805278A (zh) 2018-03-16
WO2011130343A1 (en) 2011-10-20
ES2565216T3 (es) 2016-04-01
JP5841997B2 (ja) 2016-01-13
JP2013523180A (ja) 2013-06-17
EP2558575A1 (en) 2013-02-20
EP2558574A4 (en) 2013-10-30
CA2795643C (en) 2018-07-17
CA2795636A1 (en) 2011-10-20
JP5841996B2 (ja) 2016-01-13
US20130065310A1 (en) 2013-03-14
CN102959078B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
DK2558575T3 (en) METHODS FOR GENERATION OF endogenous MARK PROTEIN.
US20120030778A1 (en) Genomic editing of genes involved with parkinsons disease
US20110023141A1 (en) Genomic editing of genes involved with parkinson's disease
US20160145645A1 (en) Targeted integration
US20110023153A1 (en) Genomic editing of genes involved in alzheimer's disease
US20120159654A1 (en) Genome editing of genes involved in adme and toxicology in animals
US20120023599A1 (en) Genome editing of cytochrome p450 in animals
SG187075A1 (en) Genome editing using targeting endonucleases and single-stranded nucleic acids
US8975042B2 (en) Fluorescent and colored proteins and methods for using them
US9771402B2 (en) Fluorescent and colored proteins and methods for using them
WO2008094316A2 (en) Novel branchiostoma derived fluorescent proteins
Heuvel et al. Supporting Information for A disease-associated XPA allele interferes with TFIIH binding and primarily affects transcription-coupled nucleotide excision repair
WO2020209332A1 (ja) 核酸結合性タンパク質